Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Dolastatin-10. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | CTSE | P14091 | 6/20 | 0.32 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolastatin-10 SCHEMBL18793204 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13135112 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL5286 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL16730776 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13378458 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL23387006 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL6423272 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126284 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126283 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL14583139 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | NOVO NORDISK A/S (DK) | 2012-08-30 | — | — | US | disclosed |
| US-8063015-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-8008252-B2 | Factor VII: remodeling and glycoconjugation of Factor VII | NOVO NORDISK A/S (DK) | 2011-08-30 | — | — | US | disclosed |
| US-20100261872-A1 | Factor VIII: remodeling and glycoconjugation of factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7795210-B2 | Protein remodeling methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2010-09-14 | — | — | US | disclosed |
| US-20100048456-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK A/S (DK) | 2010-02-25 | — | — | US | disclosed |
| US-20100015684-A1 | FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII | NEOSE TECHNOLOGIES, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20090137763-A1 | GLUCOSAMINE NUCLEOTIDE SUGARS | NEOSE TECHNOLOGIES, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090093399-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080305991-A1 | Factor IX: remodeling and glycoconjugation of factor IX | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-7439043-B2 | Galactosyl nucleotide sugars | NEOSE TECHNOLOGIES, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20080206808-A1 | GALACTOSYL NUCLEOTIDE SUGAR | NEOSE TECHNOLOGIES, INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080187955-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7399613-B2 | Sialic acid nucleotide sugars | NEOSE TECHNOLOGIES, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080146494-A1 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080070275-A1 | Factor VIII: Remodeling and glycoconjugation of factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080050772-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261872-A1 | Factor VIII: remodeling and glycoconjugation of factor VIII | F13B, F8, F13A1 | SSTR2 2629/4885CYP3A4 3439/4885FOLH1 446/4885 |
| US-20080206808-A1 | GALACTOSYL NUCLEOTIDE SUGAR | GALNT1, UGCG, GALNT3 | SSTR2 1853/4885CYP3A4 4880/4885FOLH1 255/4885 |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | SSTR2 2629/4885CYP3A4 3439/4885FOLH1 446/4885 |
| US-20120220517-A1 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods | PTMS, ANPEP, NGLY1 | SSTR2 2564/4885CYP3A4 4875/4885FOLH1 447/4885 |
| US-20100015684-A1 | FACTOR VII: REMODELING AND GLYCOCONJUGATION OF FACTOR VII | F13B, F7, HABP2 | SSTR2 2244/4885CYP3A4 3955/4885FOLH1 650/4885 |
| US-20080187955-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | EPOR, HBG2, HAMP | SSTR2 894/4885CYP3A4 4670/4885FOLH1 147/4885 |
| US-20090093399-A1 | Glycopegylation methods and proteins/peptides produced by the methods | PTMS, ANPEP, NGLY1 | SSTR2 2564/4885CYP3A4 4875/4885FOLH1 447/4885 |
| US-20100048456-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | SSTR2 2564/4885CYP3A4 4875/4885FOLH1 447/4885 |
| US-20080146494-A1 | Glycoconjugation methods and proteins/peptides produced by the methods | PTMS, DNPEP, ANPEP | SSTR2 1377/4885CYP3A4 4848/4885FOLH1 168/4885 |
| US-20080305991-A1 | Factor IX: remodeling and glycoconjugation of factor IX | F9, F13B, F13A1 | SSTR2 3611/4885CYP3A4 4535/4885FOLH1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.